Fluoxetine - Page 1 | CARLAT PUBLISHING

Fact Sheet

Fluoxetine (Prozac, Prozac Weekly) Fact Sheet [G]

November 18, 2025

Talia Puzantian, PharmD, BCPP and Daniel Carlat, MD

Dr. Carlat and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Fluoxetine’s wide spectrum of indications and long track record make it a go-to SSRI, often favored for patients who may benefit from its activating profile. Its main drawback is a high potential for drug interactions.

Clinical Guidance

Obsessive-Compulsive Disorder Diagnosis and Treatment (OCD)

November 19, 2024

Victoria Hendrick, MD and Daniel Carlat, MD

Dr. Hendrick and Dr. Carlat have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

OCD can be profoundly disabling, and many patients arrive on inpatient units after years of escalating symptoms.

Fact Sheet

Fluoxetine (Prozac, Prozac Weekly) for Children and Adolescents

September 22, 2023

Joshua Feder, MD, Elizabeth Tien, MD, and Talia Puzantian, PharmD, BCPP

Dr. Feder, Dr. Tien, and Dr. Puzantian have no financial relationships with companies related to this material.
Full Fact Sheet Editorial Information

Consider fluoxetine a first-line agent for children and adolescents with depression and anxiety disorders.

Expert Q&A

Pharmacological Treatment of Bipolar Disorder in Older Adults

January 31, 2023

John Beyer, MD

John Beyer, MD. Professor of psychiatry, Duke University Medical Center. Durham, NC. Dr. Beyer has consulted for Express Scripts. Relevant financial relationships listed for the author have been mitigated.

With numerous treatment options available for bipolar depression and mania, clinicians often struggle to navigate between medication classes in balancing side effects, efficacy, and costs. Dr. Beyer shares his expertise in choosing first-, second-, third-, and fourth-line options based on their evidence in older adults.